Company Overview
Snapshot
Founded in May 2023 by Ilan Sinai and Aviv De Morgan, Glion AI Biotherapeutics operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on research and development within the health tech and life sciences sector.
Business overview
Glion AI Biotherapeutics is a health tech and life sciences company operating in stealth mode, specializing in pharmaceuticals and drug design. The company leverages artificial intelligence, including deep learning, machine learning, and natural language processing, to optimize processes related to generic drugs, orphan drugs, and proteins. It targets the treatment of degenerative diseases, autoimmune diseases, amyotrophic lateral sclerosis (ALS), and rare diseases, serving the broader healthcare and life sciences markets.
Log in to access full profile ›Company Intelligence Q&A
- When was Glion AI Biotherapeutics founded?
- Glion AI Biotherapeutics was founded in May 2023.
- Who are the founders of Glion AI Biotherapeutics?
- The company was founded by Ilan Sinai and Aviv De Morgan.
- What is the primary sector of Glion AI Biotherapeutics?
- Glion AI Biotherapeutics operates primarily in the Health Tech & Life Sciences sector.
- What is the current employee size of Glion AI Biotherapeutics?
- Glion AI Biotherapeutics currently has 1–10 employees.